Anovulatory Uterine Bleeding in Adolescents: Comprehensive Management Notes

Introduction

Anovulatory uterine bleeding (AUB-O) = non-cyclic, unpredictable menstrual blood flow due to asynchronous sex-steroid production; diagnosis of exclusion.
Epidemiology: among the most common gynecologic issues in adolescents.
Pathophysiology: Immaturity of the hypothalamic–pituitary–ovarian (HPO) axis is chief cause (see Figure 1). Other etiologies must be ruled out (Table 1).
Typical presentations
• Oligomenorrhea/amenorrhea intermixed with prolonged or heavy bleeding.
• Quality-of-life impairment: physical, emotional, social.

Pretreatment Evaluation

Exclude pregnancy & pelvic infection.
Screen for other causes of abnormal uterine bleeding (structural, hormonal, iatrogenic, bleeding disorders, malignancy).
If bleeding-disorder work-up indicated, draw labs before estrogen or blood products; exogenous estrogen can transiently normalize von Willebrand factor.

Bleeding-Severity Classification

Category	Clinical criteria	Typical Hb
Mild	• Flow slightly ↑ or moderately ↑ (Table 2)
• Menses >7 days or cycle interval <24 days for ≥2 mo	$\ge 10$ but <12\ \text{g/dL} or normal (≥12 g/dL)
Moderate	• Moderate–heavy flow
• Menses >7 days or every 1–3 wk	$\ge10$ and <12\ \text{g/dL}
Severe	• Heavy flow ± hemodynamic instability
• Menses >7 days	<10\ \text{g/dL}
Quantification clues: clots >2.5 cm, nocturnal pad change, soiling clothes, activity limitation.

Management Overview

Algorithm 1 (mild–moderate) & Algorithm 2 (severe) summarize acute steps.

Mild Bleeding

Usually managed by observation + iron if Hb 10–12 g/dL.
Offer hormonal therapy if quality-of-life affected or contraception desired. Regimens identical to “moderate/not-actively bleeding.”
Tools: menstrual calendar (paper or app); follow-up 3–6 mo, then annually.

Moderate Bleeding

If NOT actively bleeding

Choice determined by contraception need and estrogen tolerance.

Combined Estrogen–Progestin (COC) 30–35 µg ethinyl estradiol.
Progestin-only (pills, 52-mg LNG-IUD, DMPA) if estrogen contraindicated or declined.
• Daily contraceptive progestins: norethindrone 0.35 mg or drospirenone 4 mg 24/4.
• Cyclic, non-contraceptive progestins (Table 4): norethindrone acetate 5 mg ×5–10 d/mo, micronized progesterone 200 mg ×12 d/mo, medroxyprogesterone 10 mg ×10 d/mo.
Iron for anemia; menstrual calendar; follow-up at 3 mo.

If Actively Bleeding

First-line: COC high-dose taper (hormonally active pills only):
1 pill q8 h until bleeding stops (≈48 h) → 1 pill q12 h ×2 d → 1 pill daily ×21 d → 7 inactive pills → resume cycles.
Provide antiemetic (ondansetron 4–8 mg or promethazine 12.5–25 mg) 1 h pre-dose.
Progestin-only or 52-mg LNG-IUD if estrogen CI.
Tranexamic acid (TXA) 1300 mg PO TID 1–5 d menses for patients refusing hormones and without TE risk.

Severe Bleeding

Indications for Hospitalization

Hemodynamic instability (tachycardia, hypotension, orthostasis).
Hb <7 g/dL OR <10 g/dL with active heavy bleeding.
Symptomatic anemia.
Need for IV conjugated estrogen or surgical intervention.

Initial Labs

Complete bleeding-disorder panel before estrogen/blood products (higher prevalence in severe bleeders).

Hormonal Control

Preferred: High-dose COC (30–35 µg EE + 0.3 mg norgestrel or 0.4–1 mg norethindrone). Taper:
• 1 pill q4–6 h until bleeding subsides (≈24 h) → q8 h ×3 d → q12 h ≤2 wk → daily.

Alternatives

Oral norethindrone acetate 5–10 mg up to QID → taper (3 → 2 → 1 tabs).
52-mg LNG-IUD (if provider available).
IV conjugated estrogen 25 mg q4–6 h ×≤6 doses if unstable or oral failure → switch to COC taper.
Add TXA 1300 mg TID (or aminocaproic acid) if bleeding persists >24 h on IV estrogen or platelet dysfunction.

Refractory Bleeding

Evaluate for retained clots, uterine pathology.
Consider suction curettage/D&C only as life-saving last resort; risk of Asherman syndrome.

Maintenance Therapy (Post-Control)

Decisions based on initial regimen, anemia status, and contraception desire. Use menstrual calendar; monitor Hb monthly until >10\ \text{g/dL} then q3–6 mo until >12\ \text{g/dL}.

After Estrogen-Containing Control

Hb <10 g/dL: Continuous COC 30–35 µg EE (skip placebos). Expect breakthrough spotting first 3 mo; if heavy >14 d, return to BID dosing ×2 wk.
Hb ≥10 g/dL: Pause 7 d → withdrawal bleed → cyclic COC (21/7) ≥6 mo.
Patches (norelgestromin/EE, Twirla) or vaginal rings (NuvaRing, Annovera) acceptable for non-daily preference.

After Progestin-Only Control

Hb <10 g/dL: Continue norethindrone acetate 5–10 mg daily; monthly Hb.
Hb ≥10 g/dL: 7-day hormone break → withdrawal bleed → choose:
• Cyclic progestin regimen (Table 4) if no contraception needed.
• Daily progestin-only contraceptive, DMPA IM q12 wk, 52-mg LNG-IUD, or etonogestrel implant if contraception desired.

Long-Term Monitoring & Prevention

Goals: avoid chronic anemia, endometrial hyperplasia/cancer.
If after stopping hormones cycles >3 mo apart (pregnancy −), perform endocrine evaluation: early-AM FSH, LH, TSH, prolactin, DHEA-S, 17-OHP, total testosterone to rule out PCOS, thyroid, HPO disorders.
Induce withdrawal bleed every ≤3 mo: oral micronized progesterone 200 mg qHS ×12 d/month (contains peanut oil), or medroxyprogesterone 10 mg ×10 d, or norethindrone acetate 5 mg ×5–10 d.
Endometrial biopsy if ≥2–3 yr untreated AUB-O, especially with $\text{BMI}\ge30\ \text{kg/m}^2$ or family CA history.

Prognosis

HPO maturation: % cycles ovulatory after menarche
• <12 y menarche: 50 % by 1 y • 12–13 y: 50 % by 3 y • >13 y: 50 % by 4.5 y.
Persistent anovulation (e.g., PCOS) ↑ future infertility & endometrial CA risk.

Venous Thromboembolism (VTE) Considerations

EE raises baseline adolescent VTE risk slightly; risk dose-dependent (>35 µg EE ↑).
Avoid EE in inherited/acquired thrombophilias, migraine + aura, SLE with aPL, TE history, severe liver disease, etc. (Table 5).
TXA + COC appears very low VTE risk, but still screen for TE factors.

Non-Hormonal Adjuncts

Iron: oral or IV depending on severity; start ASAP.
Antiemetics consistently with high-dose estrogen/progestin.

Patient & Family Education

Provide plain-language materials (“Basics”) and detailed sheets (“Beyond the Basics”).
Written taper instructions, danger signs (syncope, SOB, heavy recurrence).
Emphasize adherence, calendar use, follow-up scheduling.

Practical Pearls & Tips

• Schedule cyclic progestins on 1st of month—easier recall.
• Distinguish breakthrough bleeding on continuous pills vs pathologic bleeding.
• Same-day LNG-IUD preferred if expertise available; many pediatric offices lack capacity—coordinate with gynecology.
• If using continuous COC, supply 21-day packs or remove placebos to avoid accidental hormone-free interval.
• High-dose estrogen causes nausea—pre-dose antiemetics improve adherence.
• For moderate/severe bleeders, arrange close follow-up (1–3 mo) until stable.

Ethical / Practical Considerations

Shared decision-making with adolescent and caregivers, respecting confidentiality especially around contraception.
Collaboration with subspecialists for comorbid conditions (hematology for VWD, oncology during chemotherapy, etc.).

Key Numerical Cut-offs & Drug Doses (All oral unless noted)

• Mild Hb: $\ge10$ –<12\ \text{g/dL}; Moderate Hb $\ge10$ –<12; Severe Hb <10.
• COC acute taper: 1 tab q8 h → q12 h ×2 d → daily.
• Severe COC: 1 tab q4–6 h → q8 h ×3 d → q12 h ≤2 wk → daily.
• Norethindrone acetate acute: 5–10 mg QID max.
• TXA: 1300 mg TID ×1–5 d each menses.
• IV estrogen: 25 mg q4–6 h (≤6 doses).
• DMPA: 150 mg IM q12–13 wk.

High-Yield Tables / Figures Mentioned

Table 1 – Causes of AUB in adolescents by bleeding pattern.
Table 2 – Menstrual flow descriptors.
Table 3 – Selected hormonal contraceptives (EE 30–35 µg preferred).
Table 4 – Oral progestin regimens (acute & maintenance).
Table 5 – VTE risk factors (hereditary & acquired).
Figure 2 – Menstrual record chart (encourage use).
Algorithms 1 & 2 – Mild-moderate vs severe acute management.

Summary Checklist for Clinicians

✓ Rule out pregnancy, infection, structural causes.
✓ Classify severity (flow & Hb).
✓ Start iron early.
✓ Mild: observe ± hormones.
✓ Moderate active bleed: high-dose COC taper + antiemetic.
✓ Moderate non-active bleed: COC or progestin depending on contraception/counter-indications.
✓ Severe: hospitalize if unstable; high-dose COC or IV estrogen; consider TXA/hemostatics.
✓ Establish maintenance plan; monitor Hb until ≥12 g/dL.
✓ Long-term: periodic endocrine review, prevent hyperplasia, address contraception needs.
✓ Educate, document, follow up.

Anovulatory uterine bleeding (AUB-O):